What You Should Know:
– Linus Health has introduced Anywhere for Health Systems™, an innovative, FDA-listed, AI-enhanced cognitive assessment designed to address the critical issue of undetected mild cognitive impairment (MCI), a precursor to dementia.
– The new solution empowers health systems to conduct accurate and efficient cognitive evaluations remotely, significantly improving early detection rates and streamlining patient care.
Delivering Clinical-Grade Cognitive Assessments Remotely
The alarming statistic that 92% of MCI cases go undetected highlights a major gap in current healthcare practices. Traditional MCI detection methods, involving in-person screenings and lengthy neuropsychological evaluations, are often time-consuming and resource-intensive, placing a strain on already overburdened clinicians.
Anywhere for Health Systems™ offers a solution by providing a convenient and rapid assessment that patients or their care partners can administer from home via laptop, tablet, or phone, at the request of their primary care provider (PCP). This FDA Class II medical device utilizes a peer-reviewed battery of tests to assess four critical cognitive domains.
Anywhere for Health Systems™ complements Linus Health’s broader suite of cognitive health solutions, including Radar and a portfolio of digital cognitive assessments and personalized action plans. Linus Health collaborates with health systems to tailor workflows and optimize patient and provider experiences.
“This self-administered test is the solution healthcare systems have been looking for,” said John Showalter, MD, MSIS, chief strategy and product officer at Linus Health. “Used alongside our in-clinic cognitive assessment, this remote test provides additional insights into cognitive health, helping providers pinpoint concerns, refine referrals, and rule out unimpaired patients—all while enabling more personalized and effective care.”
